The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor mutational burden as a predictive biomarker for molecularly matched therapy in two independent pan-cancer cohorts.
 
Damian Tobias Rieke
Honoraria - Bayer; Bristol-Myers Squibb; Lilly; Roche
Consulting or Advisory Role - Alacris Theranostics; Bayer
 
Till de Bortoli
No Relationships to Disclose
 
Manuela Benary
No Relationships to Disclose
 
Peter Horak
Stock and Other Ownership Interests - Platomics
Honoraria - Roche Pharma AG; Trillium GmbH
Consulting or Advisory Role - Platomics
 
Mario Lamping
No Relationships to Disclose
 
Sebastian Stintzing
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb GmbH; Merck KGaA; MSD; Nordic Bioscience; Pfizer; Pierre Fabre; Roche; SERVIER
Consulting or Advisory Role - Amgen; AstraZeneca; GlaxoSmithKline; Merck KGaA; MSD; Nordic Bioscience; Pierre Fabre; Roche; Seagen; SERVIER; TERUMO
Research Funding - Amgen (Inst); Merck Serono (Inst); Pierre Fabre (Inst); Roche Molecular Diagnostics (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Lilly; Merck KGaA; Pierre Fabre; Roche; Sanofi; Sirtex Medical; Takeda
 
Inge Tinhofer
Honoraria - Merck KGaA
 
Serge Leyvraz
Consulting or Advisory Role - Bayer; Immunocore
Travel, Accommodations, Expenses - Bayer; Immunocore
 
Reinhold Schäfer
Stock and Other Ownership Interests - Cellular Phenomics and Oncology
 
Frederick Klauschen
No Relationships to Disclose
 
Ulrich Keller
No Relationships to Disclose
 
Albrecht Stenzinger
Consulting or Advisory Role - AGCT; AstraZeneca; Bayer; Bristol-Myers Squibb; Illumina; Janssen; Lilly O.; Novartis; Seagen; Takeda; Thermo Fisher Scientific
Speakers' Bureau - AstraZeneca; Bayer; Bristol-Myers Squibb; Illumina; MSD; Novartis; Roche; Thermo Fisher Scientific
Research Funding - Bayer; Bristol-Myers Squibb; Chugai Pharma; Incyte
 
Stefan Froehling
Honoraria - Amgen; Lilly; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Illumina; Roche
Research Funding - AstraZeneca (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Lilly; PharmaMar; Roche
 
Razelle Kurzrock
Leadership - CureMatch; CureMetrix
Stock and Other Ownership Interests - CureMatch; CureMetrix; IDbyDNA
Honoraria - AACR; Bicara Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; Foundation Medicine; LEK; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Roche; Turning Point Therapeutics; Wiley
Consulting or Advisory Role - Actuate Therapeutics; AstraZeneca; Bicara Therapeutics; Biological Dynamics; Caris Life Sciences; Daiichi Sankyo; Datar Genomics; Eisai; EOM Pharmaceuticals; Gaido; Iylon; Loxo; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Prosperdtx; Regeneron; Roche; Soluventis; TD2/Volastra; Turning Point Therapeutics; XBiotech
Speakers' Bureau - NeoGenomics Laboratories; Roche
Research Funding - Biological Dynamics (Inst); Boehringer Ingelheim (Inst); Debiopharm Group (Inst); Foundation Medicine (Inst); Genentech (Inst); Grifols (Inst); Guardant Health (Inst); Incyte (Inst); Konica Minolta (Inst); MedImmune (Inst); Merck Serono (Inst); OmniSeq (Inst); Pfizer (Inst); Sequenom (Inst); Takeda (Inst); Top Alliance BioScience (Inst)
Travel, Accommodations, Expenses - NCI SWOG; TargetCancer Foundation
 
Ivan Jelas
Honoraria - Bristol-Myers Squibb; Merck; Roche
 
Ulrich Keilholz
Honoraria - AstraZeneca; Bayer Schering Pharma; Bristol-Myers Squibb; Merck KGaA; MSD Oncology; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD Oncology
Speakers' Bureau - AstraZeneca; Bayer Schering Pharma; Bristol-Myers Squibb; Merck Serono; MSD Oncology; Novartis
Research Funding - AstraZeneca/MedImmune (Inst); Pfizer (Inst)